Esperion Therapeutics Inc (ESPR) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 51.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,423 shares of the biopharmaceutical company’s stock after selling 3,585 shares during the period. SG Americas Securities LLC’s holdings in Esperion Therapeutics were worth $172,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Meditor Group Ltd boosted its holdings in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after purchasing an additional 1,728,935 shares during the period. State Street Corp boosted its holdings in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after purchasing an additional 1,093,292 shares during the period. Discovery Capital Management LLC CT boosted its holdings in Esperion Therapeutics by 152.9% in the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after purchasing an additional 583,529 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Esperion Therapeutics by 12,603.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock valued at $10,098,000 after purchasing an additional 199,890 shares during the period. Finally, Lord Abbett & CO. LLC bought a new position in Esperion Therapeutics in the 2nd quarter valued at $6,432,000. Institutional investors own 92.24% of the company’s stock.

A number of research firms have recently issued reports on ESPR. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and lifted their price objective for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Chardan Capital lifted their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, December 6th. Northland Securities began coverage on shares of Esperion Therapeutics in a report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 price objective for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $60.85.

In related news, Director Nicole Vitullo sold 9,326 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the transaction, the director now owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 32.50% of the stock is owned by insiders.

Esperion Therapeutics Inc (ESPR) opened at $59.36 on Tuesday. Esperion Therapeutics Inc has a 52-week low of $10.71 and a 52-week high of $65.20. The stock has a market cap of $1,555.10, a PE ratio of -8.64 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) EPS. analysts forecast that Esperion Therapeutics Inc will post -7.3 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics Inc (ESPR) Shares Sold by SG Americas Securities LLC” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/26/esperion-therapeutics-inc-espr-shares-sold-by-sg-americas-securities-llc.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit